Metastasis-inducing S100A4 protein is associated with treatment response in patients with recent-onset rheumatoid arthritis
Background/objectives There is increasing evidence that metastasis-inducing S100A4 protein may exert pro-inflammatory and destructive effects in rheumatoid arthritis (RA). The authors have previously demonstrated that S100A4 is significantly up-regulated in RA and correlates with disease activity. T...
Gespeichert in:
| Veröffentlicht in: | Annals of the rheumatic diseases 2012-02, Vol.71 (Suppl 1), p.A15 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | Suppl 1 |
| container_start_page | A15 |
| container_title | Annals of the rheumatic diseases |
| container_volume | 71 |
| creator | Šumová, B Andrés Cerezo, L Pleštilová, L Pecha, O Jarošová, K Forejtová, Š Růžičková, O Závada, J Pavelka, K Mann, H Vencovský, J Šenolt, L |
| description | Background/objectives There is increasing evidence that metastasis-inducing S100A4 protein may exert pro-inflammatory and destructive effects in rheumatoid arthritis (RA). The authors have previously demonstrated that S100A4 is significantly up-regulated in RA and correlates with disease activity. Therefore, the authors investigated the relationship between S100A4, disease activity and response to treatment with synthetic disease modifying antirheumatic drugs (DMARDs) in patients with recent-onset RA. Methods Serum levels of S100A4 protein were determined by ELISA before and after 3 months of initiation of the DMARD treatment in 59 patients with recent-onset RA (symptom duration |
| doi_str_mv | 10.1136/annrheumdis-2011-201230.33 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1777880899</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4008562391</sourcerecordid><originalsourceid>FETCH-LOGICAL-b2153-3915f055801aa8913531df63a6f05fe2ba88956623a5f2e11b30edb6d6f4bbdf3</originalsourceid><addsrcrecordid>eNqVkEtPxCAUhYnRxHH0PxBdd-SW8qi7ycRXMupi1IUbQlvqMNp2BBo1_nlpaoxbEwK5h-_cCwehYyAzAMpPddu6tembyvokJQDDllIyo3QHTSDjMgqc7KIJIYQmWc7FPjrwfhNLIkFO0NeNCdrHFRvYtupL2z7jFRAyz_DWdcHYFluPtfddaXUwFX63YY2DMzo0pg3YGb_tWm9wBLc62Kj5kXGmjEUyXEZseKUOna2wdmHtbLD-EO3V-tWbo59zih4uzu8XV8ny7vJ6MV8mRQqMJjQHVhPGJAGtZQ6UUahqTjWPam3SQkuZM85TqlmdGoCCElMVvOJ1VhRVTafoZOwbP_TWGx_UputdG0cqEEJISWSeR-pspErXee9MrbbONtp9KiBqCFv9CVsNYasxbEVpNCej2fpgPn6d2r0oLqhg6vZxocQFI2KVCvUUeTbyRbP5z5xvs6mYpA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1777880899</pqid></control><display><type>article</type><title>Metastasis-inducing S100A4 protein is associated with treatment response in patients with recent-onset rheumatoid arthritis</title><source>BMJ Journals - NESLi2</source><creator>Šumová, B ; Andrés Cerezo, L ; Pleštilová, L ; Pecha, O ; Jarošová, K ; Forejtová, Š ; Růžičková, O ; Závada, J ; Pavelka, K ; Mann, H ; Vencovský, J ; Šenolt, L</creator><creatorcontrib>Šumová, B ; Andrés Cerezo, L ; Pleštilová, L ; Pecha, O ; Jarošová, K ; Forejtová, Š ; Růžičková, O ; Závada, J ; Pavelka, K ; Mann, H ; Vencovský, J ; Šenolt, L</creatorcontrib><description><![CDATA[Background/objectives There is increasing evidence that metastasis-inducing S100A4 protein may exert pro-inflammatory and destructive effects in rheumatoid arthritis (RA). The authors have previously demonstrated that S100A4 is significantly up-regulated in RA and correlates with disease activity. Therefore, the authors investigated the relationship between S100A4, disease activity and response to treatment with synthetic disease modifying antirheumatic drugs (DMARDs) in patients with recent-onset RA. Methods Serum levels of S100A4 protein were determined by ELISA before and after 3 months of initiation of the DMARD treatment in 59 patients with recent-onset RA (symptom duration <6 months). Clinical disease activity (DAS28, swollen joint count) and inflammation (CRP, ESR) were assessed at baseline and after 3 and 12 months. Rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibodies (ACPA) were analysed at baseline. Results After initiation of treatment, mean DAS28 (SD) significantly decreased from 5.36 (1.42) at baseline to 3.09 (1.52) at 3 months (n=59) and to 2.69 (1.19) at 12 months (n=40), respectively (p<0.0001). The levels of serum S100A4 protein were significantly higher in patients with recent-onset RA compared with healthy controls (646.60±602.60 vs 46.97±30.12 ng/ml; p<0.001) and significantly decreased after 3 months of treatment (to 388.10±521.00; p<0.001). Baseline levels of S100A4 positively correlated with RF (r=0.611; p<0.0001) and ACPA levels (r=0.471; p<0.001), but not with age, symptom duration, disease activity or inflammation. However, the levels of S100A4 corrected for confounders at baseline (r=0.403; p<0.05) as well as at 3 months after treatment (r=0.548; p<0.01) positively correlated with DAS28 after 12 months of treatment in female patients (n=28). Conclusion S100A4 levels were increased in patients with recent-onset RA and significantly decreased after the treatment. Higher levels of S100A4 in female patients with recent-onset RA were independently associated with disease activity over 12 months. Thus, high levels of S100A4 may have predictive capacity for worse treatment response with synthetic DMARDs in RA.]]></description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/annrheumdis-2011-201230.33</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>Kidlington: BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><ispartof>Annals of the rheumatic diseases, 2012-02, Vol.71 (Suppl 1), p.A15</ispartof><rights>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2012 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://ard.bmj.com/content/71/Suppl_1/A15.2.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://ard.bmj.com/content/71/Suppl_1/A15.2.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,776,780,3182,23551,27903,27904,77346,77377</link.rule.ids></links><search><creatorcontrib>Šumová, B</creatorcontrib><creatorcontrib>Andrés Cerezo, L</creatorcontrib><creatorcontrib>Pleštilová, L</creatorcontrib><creatorcontrib>Pecha, O</creatorcontrib><creatorcontrib>Jarošová, K</creatorcontrib><creatorcontrib>Forejtová, Š</creatorcontrib><creatorcontrib>Růžičková, O</creatorcontrib><creatorcontrib>Závada, J</creatorcontrib><creatorcontrib>Pavelka, K</creatorcontrib><creatorcontrib>Mann, H</creatorcontrib><creatorcontrib>Vencovský, J</creatorcontrib><creatorcontrib>Šenolt, L</creatorcontrib><title>Metastasis-inducing S100A4 protein is associated with treatment response in patients with recent-onset rheumatoid arthritis</title><title>Annals of the rheumatic diseases</title><addtitle>Ann Rheum Dis</addtitle><description><![CDATA[Background/objectives There is increasing evidence that metastasis-inducing S100A4 protein may exert pro-inflammatory and destructive effects in rheumatoid arthritis (RA). The authors have previously demonstrated that S100A4 is significantly up-regulated in RA and correlates with disease activity. Therefore, the authors investigated the relationship between S100A4, disease activity and response to treatment with synthetic disease modifying antirheumatic drugs (DMARDs) in patients with recent-onset RA. Methods Serum levels of S100A4 protein were determined by ELISA before and after 3 months of initiation of the DMARD treatment in 59 patients with recent-onset RA (symptom duration <6 months). Clinical disease activity (DAS28, swollen joint count) and inflammation (CRP, ESR) were assessed at baseline and after 3 and 12 months. Rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibodies (ACPA) were analysed at baseline. Results After initiation of treatment, mean DAS28 (SD) significantly decreased from 5.36 (1.42) at baseline to 3.09 (1.52) at 3 months (n=59) and to 2.69 (1.19) at 12 months (n=40), respectively (p<0.0001). The levels of serum S100A4 protein were significantly higher in patients with recent-onset RA compared with healthy controls (646.60±602.60 vs 46.97±30.12 ng/ml; p<0.001) and significantly decreased after 3 months of treatment (to 388.10±521.00; p<0.001). Baseline levels of S100A4 positively correlated with RF (r=0.611; p<0.0001) and ACPA levels (r=0.471; p<0.001), but not with age, symptom duration, disease activity or inflammation. However, the levels of S100A4 corrected for confounders at baseline (r=0.403; p<0.05) as well as at 3 months after treatment (r=0.548; p<0.01) positively correlated with DAS28 after 12 months of treatment in female patients (n=28). Conclusion S100A4 levels were increased in patients with recent-onset RA and significantly decreased after the treatment. Higher levels of S100A4 in female patients with recent-onset RA were independently associated with disease activity over 12 months. Thus, high levels of S100A4 may have predictive capacity for worse treatment response with synthetic DMARDs in RA.]]></description><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqVkEtPxCAUhYnRxHH0PxBdd-SW8qi7ycRXMupi1IUbQlvqMNp2BBo1_nlpaoxbEwK5h-_cCwehYyAzAMpPddu6tembyvokJQDDllIyo3QHTSDjMgqc7KIJIYQmWc7FPjrwfhNLIkFO0NeNCdrHFRvYtupL2z7jFRAyz_DWdcHYFluPtfddaXUwFX63YY2DMzo0pg3YGb_tWm9wBLc62Kj5kXGmjEUyXEZseKUOna2wdmHtbLD-EO3V-tWbo59zih4uzu8XV8ny7vJ6MV8mRQqMJjQHVhPGJAGtZQ6UUahqTjWPam3SQkuZM85TqlmdGoCCElMVvOJ1VhRVTafoZOwbP_TWGx_UputdG0cqEEJISWSeR-pspErXee9MrbbONtp9KiBqCFv9CVsNYasxbEVpNCej2fpgPn6d2r0oLqhg6vZxocQFI2KVCvUUeTbyRbP5z5xvs6mYpA</recordid><startdate>201202</startdate><enddate>201202</enddate><creator>Šumová, B</creator><creator>Andrés Cerezo, L</creator><creator>Pleštilová, L</creator><creator>Pecha, O</creator><creator>Jarošová, K</creator><creator>Forejtová, Š</creator><creator>Růžičková, O</creator><creator>Závada, J</creator><creator>Pavelka, K</creator><creator>Mann, H</creator><creator>Vencovský, J</creator><creator>Šenolt, L</creator><general>BMJ Publishing Group Ltd and European League Against Rheumatism</general><general>Elsevier Limited</general><scope>BSCLL</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>201202</creationdate><title>Metastasis-inducing S100A4 protein is associated with treatment response in patients with recent-onset rheumatoid arthritis</title><author>Šumová, B ; Andrés Cerezo, L ; Pleštilová, L ; Pecha, O ; Jarošová, K ; Forejtová, Š ; Růžičková, O ; Závada, J ; Pavelka, K ; Mann, H ; Vencovský, J ; Šenolt, L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b2153-3915f055801aa8913531df63a6f05fe2ba88956623a5f2e11b30edb6d6f4bbdf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Šumová, B</creatorcontrib><creatorcontrib>Andrés Cerezo, L</creatorcontrib><creatorcontrib>Pleštilová, L</creatorcontrib><creatorcontrib>Pecha, O</creatorcontrib><creatorcontrib>Jarošová, K</creatorcontrib><creatorcontrib>Forejtová, Š</creatorcontrib><creatorcontrib>Růžičková, O</creatorcontrib><creatorcontrib>Závada, J</creatorcontrib><creatorcontrib>Pavelka, K</creatorcontrib><creatorcontrib>Mann, H</creatorcontrib><creatorcontrib>Vencovský, J</creatorcontrib><creatorcontrib>Šenolt, L</creatorcontrib><collection>Istex</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Šumová, B</au><au>Andrés Cerezo, L</au><au>Pleštilová, L</au><au>Pecha, O</au><au>Jarošová, K</au><au>Forejtová, Š</au><au>Růžičková, O</au><au>Závada, J</au><au>Pavelka, K</au><au>Mann, H</au><au>Vencovský, J</au><au>Šenolt, L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Metastasis-inducing S100A4 protein is associated with treatment response in patients with recent-onset rheumatoid arthritis</atitle><jtitle>Annals of the rheumatic diseases</jtitle><addtitle>Ann Rheum Dis</addtitle><date>2012-02</date><risdate>2012</risdate><volume>71</volume><issue>Suppl 1</issue><spage>A15</spage><pages>A15-</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract><![CDATA[Background/objectives There is increasing evidence that metastasis-inducing S100A4 protein may exert pro-inflammatory and destructive effects in rheumatoid arthritis (RA). The authors have previously demonstrated that S100A4 is significantly up-regulated in RA and correlates with disease activity. Therefore, the authors investigated the relationship between S100A4, disease activity and response to treatment with synthetic disease modifying antirheumatic drugs (DMARDs) in patients with recent-onset RA. Methods Serum levels of S100A4 protein were determined by ELISA before and after 3 months of initiation of the DMARD treatment in 59 patients with recent-onset RA (symptom duration <6 months). Clinical disease activity (DAS28, swollen joint count) and inflammation (CRP, ESR) were assessed at baseline and after 3 and 12 months. Rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibodies (ACPA) were analysed at baseline. Results After initiation of treatment, mean DAS28 (SD) significantly decreased from 5.36 (1.42) at baseline to 3.09 (1.52) at 3 months (n=59) and to 2.69 (1.19) at 12 months (n=40), respectively (p<0.0001). The levels of serum S100A4 protein were significantly higher in patients with recent-onset RA compared with healthy controls (646.60±602.60 vs 46.97±30.12 ng/ml; p<0.001) and significantly decreased after 3 months of treatment (to 388.10±521.00; p<0.001). Baseline levels of S100A4 positively correlated with RF (r=0.611; p<0.0001) and ACPA levels (r=0.471; p<0.001), but not with age, symptom duration, disease activity or inflammation. However, the levels of S100A4 corrected for confounders at baseline (r=0.403; p<0.05) as well as at 3 months after treatment (r=0.548; p<0.01) positively correlated with DAS28 after 12 months of treatment in female patients (n=28). Conclusion S100A4 levels were increased in patients with recent-onset RA and significantly decreased after the treatment. Higher levels of S100A4 in female patients with recent-onset RA were independently associated with disease activity over 12 months. Thus, high levels of S100A4 may have predictive capacity for worse treatment response with synthetic DMARDs in RA.]]></abstract><cop>Kidlington</cop><pub>BMJ Publishing Group Ltd and European League Against Rheumatism</pub><doi>10.1136/annrheumdis-2011-201230.33</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0003-4967 |
| ispartof | Annals of the rheumatic diseases, 2012-02, Vol.71 (Suppl 1), p.A15 |
| issn | 0003-4967 1468-2060 |
| language | eng |
| recordid | cdi_proquest_journals_1777880899 |
| source | BMJ Journals - NESLi2 |
| title | Metastasis-inducing S100A4 protein is associated with treatment response in patients with recent-onset rheumatoid arthritis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T04%3A41%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Metastasis-inducing%20S100A4%20protein%20is%20associated%20with%20treatment%20response%20in%20patients%20with%20recent-onset%20rheumatoid%20arthritis&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=%C5%A0umov%C3%A1,%20B&rft.date=2012-02&rft.volume=71&rft.issue=Suppl%201&rft.spage=A15&rft.pages=A15-&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/annrheumdis-2011-201230.33&rft_dat=%3Cproquest_cross%3E4008562391%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1777880899&rft_id=info:pmid/&rfr_iscdi=true |